The ‘Heart Failure (HF) - Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of HF in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2017–2028
Heart Failure (HF) - Disease Understanding
Heart Failure (HF) is a chronic condition in which the heart muscle is incapable of pumping enough blood to meet the body's requirements for blood and oxygen. Few people face both problems simultaneously. Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. HF is triggered by structural and functional limitations in the myocardium resulting in damage to ventricular filling or the ejection of blood by the heart. The most common cause for HF is lowering the left ventricular myocardial utility along with the dysfunction of the pericardium, endocardium, heart valves or large vessels alone or in combination, ischemic heart disease, and diabetes. Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow towards the heart.
The four stages of HF are Stage A (pre-HF), Stage B (pre-HF but slightly closer to the worse phase of the disease), Stage C (Patients have been diagnosed with HF and is simultaneously dealing with the symptoms), Stage D and reduced E (HF have progressive symptoms that are difficult or slightly unable to get cured with treatment)
Heart Failure (HF) - Epidemiology
The Heart Failure (HF) epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. The epidemiology data for Heart Failure (HF) are studied through all possible divisions to give a better understanding of the Disease scenario in the 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.
According to the Centers for Disease Control and Prevention (CDC), about 5.7 million adults in the United States have heart failure. HF usually happens when the heart is unable to pump enough blood and oxygen to support other organs in the body. HF is a serious condition, but it does not mean that the heart has stopped beating. About half of people who develop heart failure die within 5 years of diagnosis.
According to the American Heart Association News, the number of people diagnosed with HF was increasing and projected to rise by 46% by 2030, resulting in more than 8 million people with HF, according to the American Heart Association’s 2017 Heart Disease and Stroke Statistics Update (link opens in new window). The number of adults living with heart failure increased from about 5.7 million (2009–2012) to about 6.5 million (2011–2014). Data are based on National Health and Nutrition Examination Survey, which is taken in stages over multiple years
A study conducted by Jackson et al. (2018) in the United States, HF affects approximately 6.5 million adults, and lifetime risk of HF is estimated to be 1 in 5 at 40 years of age. The incidence of HF increases with age, and HF prevalence in the aging US population is projected to increase by 46% between 2012 and 2030. Among hospitalizations for primary HF, the most common comorbid diagnoses were hypertension (72%), IHD (56%), diabetes mellitus (48%), chronic kidney disease (47%), and AF (43%). Among deaths with comorbid HF, the most common underlying causes were IHD (44%), hypertension (21%), and chronic obstructive pulmonary disease (21%).
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
The disease epidemiology covered in the report is segmented by:
- Prevalent Population of Heart Failure
- Diagnosed Prevalent Population of Heart Failure
- Gender-specific diagnosed prevalent cases of Heart Failure
- Age-specific diagnosed prevalent cases of Heart Failure
- NYHA class-specific diagnosed prevalent cases in the United States
- Diagnosed prevalent cases of Heart Failure with Ejection Fraction
- Diagnosed Prevalent cases of Heart Failure
According to the publisher, the total prevalent cases of HF in the 7MM was found to be 12,026,384 in 2017. The prevalent cases of HF in the 7MM are expected to increase during the study period of 2017–2028. Also, in 7MM the highest number of prevalent cases were observed in the US with 6,192,189 cases in 2017.
Report Scope
- The report covers the detailed overview of Heart Failure (HF) explaining its causes, symptoms, pathophysiology, diagnostic biomarkers, differential diagnosis, diagnosis and treatment patterns.
- The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Heart Failure (HF).
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
- The report provides the segmentation of the disease epidemiology by type-specific cases, comorbidities-related cases, and NYHA class-specific diagnosed prevalent cases of Heart Failure (HF) in the 7MM.
Key Strengths
- 10-Year Forecast of Heart Failure (HF) epidemiology
- 7MM Coverage
- Total Prevalent Cases of Heart Failure (HF)
- Prevalent Cases according to segmentation
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
1. Key Insights
